



Colloidal Oatmeal System

Nitrile Exam Gloves Powder Free, Standard Cuff

GloveOn® COATS® (colloidal oatmeal system) is a patented and unique nitrile glove technology, which contains an FDA-recognised skin protectant. These utilise the powerful benefits of all-natural oats as a coating that forms a natural, moisturising barrier between the glove and skin. This acts as a preventative measure against skin irritation and hydration dermatitis. Therefore, users who suffer from dry and itchy skin can now use GloveOn® COATS® to protect their hands while they work.



COATS® Nitrile		
Length (mm)	≥ 230	
Thickness Measurements (mm)		
Palm (centre of Palm)	0.07 ± 0.02	
Finger (13mm ± 3mm from tip)	0.09 ± 0.02	
Physical Properties	Before Ageing	After Ageing
Tensile Strength (MPa)	≥ 18	≥ 16
Elongation (%)	≥ 500	≥ 400
Inspection Levels & AQL	Inspection Level	AQL
Watertightness	G1	1.5
Physical Dimensions	S2	4.0
Tensile Strength	S2	4.0
Visual Inspection (Major)	S4	2.5
Visual Inspection (Minor)	S4	4.0
Particulate Residue	N = 5	≤ 2mg/glove
Colloidal Oatmeal Content	N = 5	≥ 5mg/glove

REORDER CODE

CTS38XXS	XX-SMALL
CTS38XS	X-SMALL
CTS38SS	SMALL
CTS38MM	MEDIUM
CTS38LL	LARGE
CTS38XL	X-LARGE

FEATURES

- Fingertip textured
- Powder free
- Not made with natural rubber latex
- Chemo drugs tested
- Lab chemical tested
- Ambidextrous
- Standard cuff
- Dawn blue colour

PACKAGING

200 gloves per box for XXS to L
180 gloves per box for XL
10 boxes per carton

REGULATORY COMPLIANCE

TGA - ARTG 164563, FDA 510(k),
EU 2016/425, REACH, EU 10/2011,
EC 1935/2004, MDD 93/42/EEC

STANDARDS

ASTM D6319, ASTM D6124,
ASTM D5151, ASTM F1671,
EN 455 part 1, 2 & 3, EN 1186,
EN 13130, CEN/TS 14234, EN 420,
EN 374 part 2, 3, 4 & 5, ISO 16523-1

PATENTS

Patent 7,691,436; Patent 7,718,240;
Patent 7,740,622; Patent 8,075,965;
Patent 8,458,818

MANUFACTURING ACCREDITATIONS

ISO 9001:2015
ISO 13485:2003
EN ISO 13485:2012

Chemotherapy Drugs and Concentration (Tested for Resistance to Permeation by Chemotherapy Drugs as per ASTM D6978-05 Test Report PN 134889A)	Minimum Breakthrough Detection Time (minutes)
Carmustine (BCNU), 3.3mg/ml (3,300 ppm)	21.9 minutes
Cisplatin, 1.0mg/ml (1,000 ppm)	>240 minutes
Cyclophosphamide (Cytosan), 20.0mg/ml (20,000 ppm)	>240 minutes
Dacarbazine (DTIC), 10.0mg/ml (10,000 ppm)	>240 minutes
Doxorubicin Hydrochloride, 2.0mg/ml (2,000 ppm)	>240 minutes
Etoposide (Toposar), 20.00mg/ml (20,000 ppm)	>240 minutes
Fluorouracil, 50.0mg/ml (50,000 ppm)	>240 minutes
Methotrexate, 25.0mg/ml (25,000 ppm)	>240 minutes
Mitomycin C, 0.5mg/ml (500 ppm)	>240 minutes
Paclitaxel (Taxol), 6.0mg/ml (6,000 ppm)	>240 minutes
Thiotepa, 10.0mg/ml (10,000 ppm)	36.0 minutes
Vincristine Sulfate, 1.0mg/ml (1,000 ppm)	>240 minutes

WARNING: Carmustine and Thiotepa, at the tested concentration, degraded COATS nitrile glove at 21.9 minutes and 36.0 minutes, respectively. The safe use of gloves in chemotherapy treatment is solely the decision of clinicians authorised to make such decision.

A brand by



Mun Australia
Toll free: 1800 456 837
munglobal.com.au



Proud Supporter of
Birthing Kit Foundation (Australia)



Protection Always On